Clinical Trials Results - National Cancer Institute

Skip to content

National Cancer Institute
U.S. National Institutes of Health | www.cancer.gov


	Clinical Trials Search Results

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups Science Serving People Español

Questions about cancer?


	1-800-4-CANCER

	LiveHelp® online chat

	NCI Highlights


	Virtual and Standard Colonoscopy Both Accurate Denosumab May Help Prevent Bone Loss Past Highlights



Results: 1 -10 of 75 Show results per page	View Search Criteria \| Help With Results


Sort By:	Version:	Format:


1.		Efficacy and Safety of Everolimus in Patients With Metastatic Colorectal Cancer Who Have Failed Prior Chemotherapy

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III, Phase II				Treatment				Active				18 and over				Pharmaceutical / Industry				CRAD001C2241 NCT00419159


2.		Treatment of Patients With Everolimus and Imatinib Mesylate Who Have Progressive Gastro Intestinal Stromal Tumors (GIST) and Are Resistant to Imatinib Mesylate

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III, Phase II				Treatment				Active				18 and over				Pharmaceutical / Industry				CRAD001C2454 NCT00510354


3.		Efficacy and Safety of Everolimus (RAD001) in Female or Male Patients 18 Years or Older With Advanced Neuroendocrine Tumors

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Active				18 and over				Pharmaceutical / Industry				CRAD001C2324 NCT00510068


4.		A Phase III Trials Program Exploring the Integration of Bevacizumab, Everolimus (RAD001), and Lapatinib Into Current Neoadjuvant Chemotherapy Regimes for Primary Breast Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Genetics, Treatment				Active				18 and over				Other				GBG 44 EudraCT No.: 2006-005834-19, NCT00567554

Last Modified: 10/19/2006 First Published: 10/25/2004


5.		Phase I/II Study of Gefitinib and Everolimus in Patients With Stage IIIB or IV or Recurrent Non-Small Cell Lung Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Active				18 and over				NCI				MSKCC-04033 NCT00096486


6.		RAD001 Plus Docetaxel in Patients With Metastatic Breast Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Active				18 and over				Other				2004-0758 NCT00253318


7.		Trastuzumab and RAD001 in Patients With Human Epidermal Growth Receptor 2 (HER-2) Overexpressing Breast Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Active				18 and over				Other				2005-0471 NCT00317720


8.		Sorafenib and RAD001 Renal Cell Carcinoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Active				21 and over				Other				UCSF06523 NCT00384969


9.		Randomized Phase I/II of RAD001 in Advanced Hepatocellular Carcinoma (HCC)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Biomarker/Laboratory analysis, Treatment				Active				20 to 75				Other				CRAD001C2453 NCT00390195


10.		Dosing and Effectiveness Study of Sorafenib and RAD001 in the Treatment of Patients With Advanced Kidney Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Active				18 and over				Other				SCRI GU 44 CRAD001C2480, NCT00392821

Select All on One Page


					1 2 3 4 Next >

| | | | | | | |

A Service of the National Cancer Institute